Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Income towards Parent Company (2024 - 2025)

Historic Income towards Parent Company for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to -$1.4 million.

  • Kairos Pharma's Income towards Parent Company fell 50769.23% to -$1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$5.2 million, marking a year-over-year change of. This contributed to the annual value of -$3.0 million for FY2024, which is 7158.31% down from last year.
  • Per Kairos Pharma's latest filing, its Income towards Parent Company stood at -$1.4 million for Q2 2025, which was down 50769.23% from -$1.3 million recorded in Q1 2025.
  • In the past 5 years, Kairos Pharma's Income towards Parent Company registered a high of -$234000.0 during Q2 2024, and its lowest value of -$1.6 million during Q4 2024.